Human antibody production in SCID mice implanted with human PBMCs
. | Day 21 . | . | Day 34 . | . | ||
|---|---|---|---|---|---|---|
| Treatment group . | - B cells . | + B cells . | - B cells . | + B cells . | ||
| PBS | NT | > 500 | 0 | > 500 | ||
| DI-Leu16-IL-2 (days 11-15) | NT | 64.1 ± 25.1 | 0.83 | 88.3 ± 36.5 | ||
| Rituximab (day 7) | NT | 14.3 ± 0.25 | 9.1 | 6.2 ± 0.62 | ||
| Combination | NT | 9.5 ± 0.45 | 6.0 | 5.8 ± 0.27 | ||
. | Day 21 . | . | Day 34 . | . | ||
|---|---|---|---|---|---|---|
| Treatment group . | - B cells . | + B cells . | - B cells . | + B cells . | ||
| PBS | NT | > 500 | 0 | > 500 | ||
| DI-Leu16-IL-2 (days 11-15) | NT | 64.1 ± 25.1 | 0.83 | 88.3 ± 36.5 | ||
| Rituximab (day 7) | NT | 14.3 ± 0.25 | 9.1 | 6.2 ± 0.62 | ||
| Combination | NT | 9.5 ± 0.45 | 6.0 | 5.8 ± 0.27 | ||
Human antibodies were quantitated by anti-IgG ELISA and represent the average values and standard errors of all 6 animals per group in μg/mL. Antibodies detected in the - B-cell group show the contribution of rituximab and DI-Leu16-IL-2 (both human IgG) to the total circulating antibody. NT indicates not tested.